Keyword: Randall Stanicky
When Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer.
It was nearly two years ago that activist investors began urging Perrigo to hive off its specialty pharma unit. Now, it’s finally happening.
Billionaire David Tepper has permission to make an activist run at Allergan. Will he use it—and if so, how?
Just five months after Allergan’s CEO said the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.